Αποτελέσματα Αναζήτησης
Not starting dialysis, or stopping dialysis, is a valid treatment option in older people with cancer. The general public considers dialysis to be life-saving, but regretfully this treatment can only be viewed as life-prolonging, and it worsens quality of life while increasing the burden of care.
15 Ιαν 2017 · Treating cancer patients who are undergoing hemodialysis, or who have chronic kidney disease, is a multidisciplinary effort by oncologists and nephrologists. One study has shown that, when critically ill, between 13% and 42% of cancer patients develop AKI, and approximately 8% to 60% receive renal replacement therapy, depending on the ...
4 Δεκ 2019 · Among trials using CrCl or eGFR exclusion criteria, thresholds were usually > 45 mL/min/1.73 m 2, and severe CKD thresholds were infrequently used. 1 Under-representation of patients with CKD in cancer trials denies cancer therapies that could potentially improve outcomes and survival.
10 Ιουλ 1999 · Patients maintained on dialysis are potentially at increased risk of cancer for several reasons, including: the presence of chronic infection, especially in the urinary tract; a weakened immune system; previous treatment with immunosuppressive or cytotoxic drugs; nutritional deficiencies; and altered DNA repai. 1 in addition, the underlying ...
24 Ιαν 2017 · The overall risk of some cancers is increased in patients receiving regular dialysis treatment due to chronic oxidative stress, a weakened immune system and enhanced genomic damage. These patients could benefit from the same antineoplastic treatment delivered to patients with normal renal function, but a better risk/benefit ratio could be ...
25 Ιουλ 2020 · The kidneys also serve as a major route of excretion for metabolites, including metabolites that are released from cancer cells destroyed by the treatment (ie, uric acid in tumour lysis syndrome). 3 For these reasons, drug concentrations and dosing are adjusted in patients with impaired renal function to reduce toxicity, especially for small mol...
1 Ιουλ 2024 · We aimed to synthesize available data on cancer treatments in HD patients using PubMed database, FDA labels, summary of product characteristics (SmPC), FDA and EMA approval documents, guidelines and finally case reports for which relevant pharmacokinetic (PK) data is available.
